# First in Human, Single Ascending Dose Study

> **NCT05844592** · PHASE1 · COMPLETED · sponsor: **Innovo Therapeutics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** INV-101

## Key facts

- **NCT ID:** NCT05844592
- **Lead sponsor:** Innovo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2022-07-16
- **Final completion:** 2022-08-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844592, "First in Human, Single Ascending Dose Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05844592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*